NCT01999738 (Clinical Trial / EC1456)

Study Title
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors NCT01999738

Trial Description
Phase 1, multicenter, open-label, non-randomized, dose-escalation oncology study to evaluate the administration of EC1456, BIW on Weeks 1 and 2 of a 4-week schedule (Part A), and to assess preliminary efficacy results in focused patients with triple-negative breast cancer (TNBC), advanced non-small cell lung cancer (NSCLC), ovarian cancer and hepatocellular carcinoma (HCC) (10 patients each) treated at the MTD (Part B).

This trial is sponsored by Endocyte. [1]

Study Data

  • Condition:
    • Solid Tumors
    • Triple-Negative Breast Cancer
    • Advanced Non-Small Cell Lung Cancer
    • Ovarian Cancer
    • Hepatocellular Carcinoma
  • Interventions:
    • Drugs used in this trial
      • etarfolatide (EC20)
      • EC1456
  • Phase: I
  • Estimated Enrollment: 30
  • Start: October 2013
  • Estimated Completion: July 2016
  • Last verified: August 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: October 1, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.